Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) had its target price lifted by stock analysts at BMO Capital Markets from $13.00 to $24.00 in a research note issued on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target points to a potential upside of 209.68% from the stock’s current price.

Several other research analysts have also commented on TTPH. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. HC Wainwright started coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They set a “buy” rating and a $15.00 price objective for the company. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $8.00 to $15.00 in a research note on Wednesday, July 26th. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. Finally, BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $12.96.

Shares of Tetraphase Pharmaceuticals (TTPH) traded up 6.90% during midday trading on Wednesday, reaching $7.75. 2,411,344 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $6.68 and its 200 day moving average price is $7.29. The company’s market cap is $395.66 million. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.07). The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company’s revenue was up 28.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.47) EPS. Equities analysts anticipate that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BMO Capital Markets Boosts Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target to $24.00” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/04/bmo-capital-markets-boosts-tetraphase-pharmaceuticals-inc-ttph-price-target-to-24-00.html.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the sale, the insider now owns 17,500 shares of the company’s stock, valued at approximately $105,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.50% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in TTPH. AXA purchased a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $132,000. Citadel Advisors LLC grew its position in Tetraphase Pharmaceuticals by 18.6% during the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after purchasing an additional 2,496 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $147,000. Voya Investment Management LLC grew its position in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the last quarter. Finally, UBS Group AG grew its position in Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares during the last quarter. 41.73% of the stock is currently owned by institutional investors.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

The Fly

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.